NO991776L - Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer - Google Patents

Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer

Info

Publication number
NO991776L
NO991776L NO991776A NO991776A NO991776L NO 991776 L NO991776 L NO 991776L NO 991776 A NO991776 A NO 991776A NO 991776 A NO991776 A NO 991776A NO 991776 L NO991776 L NO 991776L
Authority
NO
Norway
Prior art keywords
acid amides
phosphodiesterase inhibitors
aminothiophenecarboxylic
aminothiophenecarboxylic acid
phosphodiesterase
Prior art date
Application number
NO991776A
Other languages
English (en)
Norwegian (no)
Other versions
NO991776D0 (no
Inventor
Rochus Jonas
Pierre Schelling
Franz-Werner Kluxen
Maria Christadler
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO991776D0 publication Critical patent/NO991776D0/no
Publication of NO991776L publication Critical patent/NO991776L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO991776A 1996-10-15 1999-04-14 Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer NO991776L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19642451A DE19642451A1 (de) 1996-10-15 1996-10-15 Aminothiophencarbonsäureamide
PCT/EP1997/005531 WO1998016521A1 (de) 1996-10-15 1997-10-08 Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren

Publications (2)

Publication Number Publication Date
NO991776D0 NO991776D0 (no) 1999-04-14
NO991776L true NO991776L (no) 1999-06-09

Family

ID=7808775

Family Applications (1)

Application Number Title Priority Date Filing Date
NO991776A NO991776L (no) 1996-10-15 1999-04-14 Aminotiofenkarboksylsyreamider og anvendelse derav som fosfodiesteraseinhibitorer

Country Status (26)

Country Link
US (1) US6143777A (pt)
EP (1) EP0934301B1 (pt)
JP (1) JP4243352B2 (pt)
KR (1) KR100479811B1 (pt)
CN (1) CN1110493C (pt)
AR (1) AR009985A1 (pt)
AT (1) ATE202347T1 (pt)
AU (1) AU725741B2 (pt)
BR (1) BR9712321A (pt)
CA (1) CA2268886C (pt)
CZ (1) CZ297253B6 (pt)
DE (2) DE19642451A1 (pt)
DK (1) DK0934301T3 (pt)
ES (1) ES2159851T3 (pt)
GR (1) GR3036341T3 (pt)
HK (1) HK1020724A1 (pt)
HU (1) HUP9904703A3 (pt)
NO (1) NO991776L (pt)
PL (1) PL192109B1 (pt)
PT (1) PT934301E (pt)
RU (1) RU2184731C2 (pt)
SI (1) SI0934301T1 (pt)
SK (1) SK283807B6 (pt)
TW (1) TW438791B (pt)
WO (1) WO1998016521A1 (pt)
ZA (1) ZA979199B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727258B2 (en) * 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
WO1999067202A1 (en) * 1998-06-19 1999-12-29 Syngenta Participations Ag . Process for preparation of pyrimidinone derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
JP2005504806A (ja) * 2001-09-21 2005-02-17 スミスクライン・ビーチャム・コーポレイション 化合物
WO2003029242A1 (en) * 2001-10-04 2003-04-10 Smithkline Beecham Corporation NF-λB INHIBITORS
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
AU2003255148A1 (en) * 2002-07-24 2004-02-09 Mitsui Chemicals, Inc. Process for producing 2-alkyl-3-aminothiophene derivative
US7179836B2 (en) * 2002-09-20 2007-02-20 Smithkline Beecham Corporation Chemical compounds
FR2875807B1 (fr) 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) * 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
BRPI0917719A2 (pt) * 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
RU2503671C1 (ru) * 2012-07-31 2014-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ
RU2501795C1 (ru) * 2012-10-01 2013-12-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
RU2722176C1 (ru) * 2019-09-06 2020-05-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US5753692A (en) * 1992-02-19 1998-05-19 Industrial Technology Research Institute Medicinal thiophene compounds
US5356926A (en) * 1992-02-24 1994-10-18 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion
DE4230755A1 (de) * 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
DE4317076A1 (de) * 1993-05-21 1994-11-24 Bayer Ag Benzthiophencarbonsäureamid-S-oxide
DE69507197T2 (de) * 1994-05-31 1999-05-27 Bayer Ag Aminobenzofuryl- und -thienylderivate
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
WO1998015545A1 (en) * 1996-10-08 1998-04-16 Eli Lilly And Company New serotonin 5-ht1f agonists
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use

Also Published As

Publication number Publication date
GR3036341T3 (en) 2001-11-30
RU2184731C2 (ru) 2002-07-10
ATE202347T1 (de) 2001-07-15
US6143777A (en) 2000-11-07
JP4243352B2 (ja) 2009-03-25
CN1110493C (zh) 2003-06-04
CZ124099A3 (cs) 1999-07-14
CN1233246A (zh) 1999-10-27
DK0934301T3 (da) 2001-10-08
TW438791B (en) 2001-06-07
NO991776D0 (no) 1999-04-14
CZ297253B6 (cs) 2006-10-11
WO1998016521A1 (de) 1998-04-23
DE19642451A1 (de) 1998-04-16
SI0934301T1 (en) 2001-12-31
EP0934301A1 (de) 1999-08-11
PL192109B1 (pl) 2006-08-31
CA2268886C (en) 2008-05-20
ES2159851T3 (es) 2001-10-16
PT934301E (pt) 2001-10-31
JP2001501957A (ja) 2001-02-13
SK43299A3 (en) 2000-04-10
HUP9904703A2 (hu) 2001-05-28
AR009985A1 (es) 2000-05-17
AU4945197A (en) 1998-05-11
HUP9904703A3 (en) 2001-06-28
DE59703869D1 (de) 2001-07-26
HK1020724A1 (en) 2000-05-19
BR9712321A (pt) 1999-08-31
KR100479811B1 (ko) 2005-03-30
EP0934301B1 (de) 2001-06-20
PL332802A1 (en) 1999-10-11
AU725741B2 (en) 2000-10-19
CA2268886A1 (en) 1998-04-23
SK283807B6 (sk) 2004-02-03
KR20000049154A (ko) 2000-07-25
ZA979199B (en) 1998-05-11

Similar Documents

Publication Publication Date Title
DK0934301T3 (da) Aminothiophencarboxylsyreamider og anvendelse deraf som phosphodiesteraseinhibitorer
DK0922697T3 (da) Substituerede pyrazolylbenzensulfonamider og anvendelse deraf som cyclooxygenase II-inhibitorer
CY2010015I2 (el) Φθοροαλκοξυ-υποκατεστημενα βeναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης
NO991922L (no) Heteroarylsuccinamider og deres anvendelse som metalloproteinaseinhibitorer
NO990700D0 (no) Propionsyrederivater og anvendelsen herav
NO20012688L (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO990296D0 (no) HPPD-genet og inhibitorer
NO20012245D0 (no) Anthranilsyreamider og anvendelse derav som medikamenter
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
DK0832061T3 (da) Benzamidderivater og anvendelse deraf som vasopressin-antagonister
DK0944590T3 (da) Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer
IS4906A (is) Nýjar amínósýruafleiður og notkun þeirra sem þrombínhemla
NO942247D0 (no) Korrosjonsinhibitor og anvendelse derav
NO954944D0 (no) Antikorrosjonspigment og anvendelse derav
HUP9904165A3 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
IS4312A (is) Skvalen lígasa efnahemlar og notkun theirra
NO954321L (no) 4-aryl-4-hydroksy-tetrahydropyraner og 3-aryl-3-hydroksy-tetrahydrofuraner som 5-lipoksygenase-inhibitorer
NO20003142L (no) Substituerte isokinolin-derivater og anvendelse derav som antikrampemidler
DK1228026T3 (da) 15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
DK1036319T3 (da) Fremgangsmåde til opnåelse af L-dihydroorotsyre og anvendelse deraf
NO992310D0 (no) Inhibitorer og deres anvendelse i oljer
NO983556L (no) Formulering og anvendelse
IT1292010B1 (it) Ganasce per cristallo
NO976006L (no) Kombinert langsgÕende og tverrgÕende sporf°lging

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application